The global sales of medical cyclotron are estimated to be worth USD 247.3 million in 2025 and are anticipated to reach a value of USD 636.7 million by 2035. Sales are projected to rise at a CAGR of 6.4% over the forecast period between 2025 and 2035. The revenue generated by medical cyclotron in 2024 was USD 232.4 million.
The high demand for diagnostic equipment and rising usage of radiopharmaceuticals in healthcare impel market growth. The cyclotron is one of the key equipment in the production of radionuclides for research, diagnosis, and treatment of diseases like cancer, Parkinson's, and Alzheimer's. Cyclotrons are normally the key tools of choice in all activities such as medical imaging and therapeutics.
The growth in demand for cyclotrons also includes the capability of producing various radionuclides used in PET and SPECT imaging. This cutting-edge imaging technique has served as the foundation for an increasing number of medical discoveries, as well as the earliest and most accurate identification of disorders in all aspects of modern medicine.
Global Medical Cyclotron Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2024 | USD 232.4 million |
| Estimated Size, 2025 | USD 247.3 million |
| Projected Size, 2035 | USD 636.7 million |
| Value-based CAGR (2025 to 2035) | 6.4% |
Besides traditional healthcare use, cyclotron technology is also moving into the utility in research centers and academic institutions toward innovation. This development of cyclotron operations and design contributes to boosting the market, as well as the demand for cyclotron systems for the production of radiopharmaceuticals.
Structured integration of automation and workflows into the systems has enabled better operational efficacy while making the radiopharmaceutical production process less complex.
The requirement of these compact cyclotron designs, complemented with advanced types and products of shields, has paved the way for cyclotron installation at a diversified choice of places, eliminating the constraints on extended setting up infrastructure.
The installed base of medical cyclotron will keep on accelerating with the healthcare sector adopting more advanced technology in diagnostic and therapeutic arms of patient care. Aid from governments and nongovernment agencies in recognizing radionuclides as a broad solution to dealing with some overwhelming health threats has nonetheless contributed to the growth of demand for safe and effective cyclotron technology.
With growing funding and a steady trend for enhancing development in healthcare infrastructure, the sales medical cyclotron is expected to remain at the forefront of medical innovation, creating further economic opportunities for stakeholders within the value chain.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
A comparative analysis of fluctuations in compound annual growth rate (CAGR) for the medical cyclotron market between 2024 and 2025 on a six-month basis is shown below.
By this examination, major variations in the performance of these markets are brought to light, and also trends of revenue generation are captured hence offering stakeholders useful ideas on how to carry on with the market’s growth path in any other given year. January through June covers the first part of the year called half1 (H1), while half2 (H2) represents July to December.
The table below compares the compound annual growth rate (CAGR) for the global medical cyclotron revenue from 2024 to 2025 during the first half of the year. This overview highlights key changes and trends in revenue growth, offering valuable insights into market dynamics.
H1 covers January to June, while H2 spans July to December. In the first half (H1) of the decade from 2024 to 2034, the business is predicted to surge at a CAGR of 7.1%, followed by a slightly lower growth rate of 6.8% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.1% (2024 to 2034) |
| H2 | 6.8% (2024 to 2034) |
| H1 | 6.4% (2025 to 2035) |
| H2 | 5.9% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 6.4% in the first half and projected to lower at 5.9% in the second half. In the first half (H1) the market witnessed a decrease of 70 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
Rising need for Diagnostic Radioisotopes Propelling Demand Medical Cyclotron Installations
Global rise in the cases of neurological diseases is mainly attributed to rising populations and shifts in lifestyle patterns. Cyclotrons ensure huge production of radionuclides required for studying and diagnosing such diseases.
It was reported by the Health Economics and Outcomes Research LTD in 2023 that 87 million people had early Alzheimer's disease and 32 million people lived with mild, moderate, or severe dementia. Meanwhile, Alzheimer's disease comprises 60-80% of dementia cases and is expected to witness a threefold rise, reaching 135 million cases by 2050.
In the same spectrum, WHO reported in 2019 that more than 8.5 million people were suffering from Parkinson's disease and that the DALYs of this condition had risen by 81% since peaking in 2000.
This emerging burden has necessitated a move towards advanced diagnostic modalities, which include PET and SPECT imaging based on radionuclides produced using medical cyclotrons. Such nuclear imaging techniques encourage very early diagnosis and personalized treatments of neurological disorders, which add to improved outcomes.
Emerging incidences of AD and PD provoke the demand for testing technologies for cyclotrons. Some of these technologies are today accepted as the pillars of the global contribution to the fight against neurodegenerative disorders.
Increasing Adoption of Cyclotron-Based Ga-68 Production Drive Growth in Medical Cyclotron Market
The cyclotron production of Ga-68 has grown to overtake its Ge-68/Ga-68 generator tradition due to perennial high costs and limited availability of generators, which forced healthcare facilities and manufacturers toward an alternative. Gallium-68 (Ga-68) is a radionuclide widely utilized in nuclear medicine for diagnostics imaging, more specifically positron emission tomography (PET) scans.
Ga-68 plays a major role in the detection of prostate cancer using Ga-68 PSMA (Prostate-Specific Membrane Antigen) tracers. Such tracers aid in visualizing prostate cancer cells with extreme precision, thereby facilitating their earlier identification and treatment planning.
According to the IAEA, with each operation, cyclotrons are capable of producing 1 Curie (Ci) of Ga-68 in contrast to 40 to 50 mCi from generators. Also, the technical document from the IAEA on cyclotron-based production of Ga-68 has become one of the most downloaded materials indicative of the rising popularity of that method. .
This sector is benefitting greatly from the growing popularity of this trend in terms of demand for advanced cyclotron systems capable of Ga-68 production. Therefore, cyclotron systems are now becoming indispensable in the production of Ga-68-based PSMA tracers used for prostate cancer diagnosis.
As healthcare providers and research facilities continue to adapt to the use of cyclotron technology for Ga-68 production, the trend is bound to drive further innovation and expansion of the global cyclotron market that will open broader access to life-saving diagnosis and therapy.
Growing Demand for Compact Cyclotrons in Developing Markets
The merging focus on decentralized healthcare infrastructure has opened up a great opportunity for compact cyclotrons in emerging markets. As opposed to conventional cyclotrons that require large facilities and heavy investments, compact cyclotrons increase the portability factor and are more economical and adaptable. Therefore, they are best suited for regions with limited budgets for health care or in medical facilities where space is inadequate.
Increasing demand and change to secure advanced diagnostic tools due to the frequency of cancer and non-communicable diseases form an incentive for emerging markets. As chronic diseases are increasing rapidly, it creates an opportunity for compact cyclotrons to manufacture important radionuclides such as FDG locally. This factor, thereby, reduces dependence on costly imports while lessening logistical problems in the transportation of radiopharmaceuticals.
This has led to the manufacturers encouraging the development of compact cyclotron models for small hospitals and diagnostic centers. The companies that cater to this demand and provide scalable, affordable solutions will greatly benefit in this competitive race by providing healthcare in emerging markets with both private and government funding.
The burgeoning acceptance of compact cyclotrons for nuclear medicine thus will help broaden access to nuclear medicine, which will result in better patient care and immense opportunities for market participants across the globe.
High Initial Investment and Maintenance Costs of these Devices Hampers Market Growth
The main restraining factors in the market for medical cyclotron systems include high initial costs for purchasing and setting up cyclotron systems and maintenance costs. Cyclotrons can be associated with several benefits, such as the ability to produce a wide range of radionuclides and their ability to easily produce within a quite large range of production capacities.
However, the purchase and installation of cyclotron systems may likely be very expensive. Such high up-front capital investments may pose a significant hindrance to smaller health facilities, research institutions, and emerging markets operating under budgetary constraints.
Furthermore, the maintenance and operating costs of cyclotrons are enormous. Most cyclotron systems require special skills for their successful operation, and repairs and upkeep usually can be accounted for the extra shipping and operational expenses. There may also be unforeseen repair costs or the need for technological up-gradation of cyclotron systems.
As a result, though the market for cyclotron production of radionuclide-based is indeed on an upturn, the high cost associated with their acquisition and maintenance can cause a bottleneck if recently introduced to the markets, especially for regions where health services are funded hardly. Hence, such factors might restrict market growth potential, be it small healthcare clinics or emerging markets wherein budget issues are prevailing.
The global sales of medical cyclotrons recorded a CAGR of 3.2% during the historical period between 2020 and 2024. The growth of the medical cyclotron diagnostics industry was positive as it reached a value of USD 636.7 million in 2035 from USD 247.3 million in 2025.
Historically, this sector has evolved with advancements in nuclear medicine and medical imaging. Since their introduction, cyclotrons have served primarily in the production of positron emission tomography (PET) tracers deployed in the diagnosis of various diseases, ranging from cancers to cardiovascular diseases and neurological disorders.
Because of their high cost and technical complexity, the medical use of cyclotrons was initially limited to large research centers or hospitals. Over the years, however, systems for cyclotron installations introduced incrementally, in response to the expanding need for noninvasive diagnostic tools.
The beginning of radiopharmaceuticals such as FDG for PET imaging played a crucial role in turning cyclotrons into practical devices for medical use. The increased recognition of the ability of cyclotrons to manufacture radiopharmaceuticals other than FDG, such as Ga-68, has also encouraged their adoption. As the global healthcare space progressed, so too did the demand for advanced diagnostics, leading to a rise in cyclotron installations.
Nearly all cyclotron are shifting towards increasing automation. There may come a time very soon when, due to the increasing demand for radiopharmaceuticals, manufacturers will direct most of their attention to designing systems that would permit fully automated production processes. This would permit such facilities to enhance workflows by perhaps reducing the dependence on skilled operators, rendering cyclotron technology much more viable and efficient.
The other futuristic aspect is the gearing up towards smaller and cheaper systems of cyclotrons. As witnessed in the latest years with the increase in compact cyclotrons, the industry is inclined to witness proceedings that will facilitate the reduction of the physical space occupied by these systems, thus cheapening the systems.
This will allow cyclotrons to be installed in smaller hospitals, outpatient centers, and even mobile units, expanding access to radiopharmaceutical production globally.
Tier 1 companies are the major companies as they hold a 62.5% share worldwide. These players companies are categorized for their extensive market reach, advanced technological capabilities, and ability to invest in large-scale production, positioning them as leaders in innovation and overall market share.
They dominate the industry by offering a wide range of products and solutions with high efficiency and reliability. Prominent companies within tier 1 include Sumitomo Heavy Industries, Ltd., General Electric Company, IBA RadioPharma Solutions and Siemens AG
Tier 2 companies are relatively smaller as compared with tier 1 players. The tier 2 companies hold a share of 24.5% worldwide. These companies are considered competitive but typically focus on more specific or niche markets and emerging technologies.
While they may lack the large-scale production and market influence of Tier 1 companies, they can still offer specialized solutions and innovations within their target sectors. Key Companies under this category include Advanced Cyclotron Systems Inc., Best Medical International Inc., Varian Medical Systems Inc., Ionetix Corporation, Alcen and Isosolution Inc.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The section below covers the industry analysis for the medical cyclotron market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with a CAGR of 1.3% through 2035. In South Asia & Pacific, India is projected to witness the highest CAGR in the market of 4.8% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 1.3% |
| Germany | 1.4% |
| India | 4.8% |
| Italy | 1.9% |
| United Kingdom | 1.5% |
| China | 4.2% |
The United States dominates the global market with high share in 2024. The United States is expected to exhibit a CAGR of 1.3% throughout the forecast period (2025 to 2035).
In the United States, the rapidly advancing radiopharmaceutical development is a major thrust of the medical cyclotron market. With every pharmaceutical company and research institute developing new tracers and their respective therapeutic isotopes for ailments of cancer, Alzheimer's, and cardiovascular diseases, the nation is receptive for new treatment regimens.
The revolution demand for new isotopes has allowed the introduction of powerful medical cyclotrons, providing advanced delivery of radionuclides-high purity radionuclide with multiple types. The USA agencies have expedited approval throughout by novel ones under FDA and provided much impetus for further investment.
There is indeed a growing uptake of installations and upgrades because, as new radiopharmaceuticals advance in the pipeline, all eyes are on throughput rapidly increasing. This solidly reflects the forefield of innovation in a link of nuclear medicine that benefits in the healing of healthcare.
In 2024, the United Kingdom held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 1.5%.
Parkinson's disease is the fastest-growing neurological disorder across the globe, with its prevalence escalating in the UK. According to Parkinson's UK, nearly 153,000 people in the UK have Parkinson's, meaning that it affects one out of every 37 individuals across their lifetime. Sources estimated projecting 128,000 cases in England for 2023, followed by 12,900 in Scotland, 8,300 in Wales, and 4,200 diagnoses in Northern Ireland.
Such figures bring into sharp focus the importance of the absolute progression towards more technologically advanced diagnosis and treatment options. Medical cyclotrons are the principal producers of radiopharmaceuticals utilized in PET scans for early diagnosis and improved treatment of Parkinson's disease.
The demand for radionuclide cyclotron production is strongly supported by the increasing rate of Parkinson's across the United Kingdom.
This emphasizes the great need for investment in infrastructure for nuclear medicine that could positively benefit the outcomes for people who have this very debilitating illness.
China occupies a leading value share in East Asia market in 2024 and is expected to grow with a CAGR of 4.2% during the forecasted period.
China is currently booming in nuclear medicine infrastructure, propelled by growing demands for healthcare together with the in-course embrace of government support. China's increasing number of cancer and chronic disease cases creates an urgent need for advanced diagnostic and therapeutic solutions. A crucial role is played by nuclear medicine, particularly PET and SPECT imaging in aiding early detection of these diseases, warranting increased demand for medical cyclotrons that generate necessary radiopharmaceuticals.
The Chinese government has put large amounts into nuclear medicine technology that eventually seeks better healthcare delivery and accessibility. A great example of the efforts made by China is Isotope's launch of the Fuzhi Intelligent Nuclear Medicine System (V1.0) during the 2023 Annual Academic Conference of the Chinese Society of Nuclear Medicine. Innovation in this field highlights the important steps that the country is taking towards modernizing its nuclear medicine facilities, using cutting-edge technologies to benefit patients.
The expansion of Chinese nuclear medicine together with increasing technological development are now establishing China as an emergent leader in the global nuclear medicine market; giving vast chances for the medical cyclotron sector to fulfill this mounting demand for radiopharmaceuticals.
The section contains information about the leading segments in the industry. Based on product type, Ring Cyclotron is expected to account 55.8% of the global share in 2025.
| Product Type | Ring Cyclotron |
|---|---|
| Value Share (2025) | 55.8% |
By product type, ring cyclotron is expected to hold a share of 55.8% in 2025 primarily due to its higher efficiency and capacity for producing a broader range of radionuclides, which are essential for nuclear medicine applications.
Ring cyclotrons present elevated production rates, allowing for the production of large amounts of radionuclides most appropriate to meet the world's rising need for radiopharmaceuticals in diagnostics and treatment aspects most critical for cancer therapeutics.
They are also more flexible; capable of producing PET and SPECT radionuclides, which is increasingly important with wider ranges of radiopharmaceuticals required for various medical applications.
In addition, the ring cyclotrons are more efficient, as the gross production period has been improved, and the overall yield is much higher than the previous ones. Further, regarding efficiency, it has fewer operational costs associated with it since it caters to the straightforward needs of hospitals and research centers, which depend on the continuous availability of isotopes.
| By End User | Pharmaceutical Companies |
|---|---|
| Value Share (2025) | 58.2% |
Pharmaceutical companies will account for 58.2% of the indication segment in 2025, and exhibit the highest CAGR in the forecast period.
Radiopharmaceuticals are items the pharmaceutical industry manufactures, distributes, and markets for diagnostic medical use and therapies. This industry has a very high bearing on the supply chain, especially the production of radionuclides that are involved in PET and SPECT scans.
Due to a rise in the number of cases of cancer and neurological disorders, there will be a growing demand for radiopharmaceuticals around the globe, and this even in the face of market turmoil and the constraints of the COVID-19 pandemic is intended to improve things in the near term. Hence, pharmaceutical companies will drive the market for cyclotrons.
Such corporations are urged to produce new generation cyclotron technologies, including ring-like cyclotrons, with an eye to highly scalable production of radiopharmaceuticals itself. Such companies need dependable mass production capabilities to meet hospitals' and specialized clinics' needs, thus positioning themselves as major stakeholders.
Key players in the medical cyclotron market are focusing on developing high-energy, high-capacity cyclotrons to produce a broader range of isotopes for advanced diagnostics and treatments. Additionally, there is a strong emphasis on improving proton beam acceleration technology and enhancing automation to increase efficiency and meet the growing demand for radiopharmaceuticals.
Recent Industry Developments in Medical Cyclotron Market
In terms of service, the industry is divided into AVF Cyclotron and Ring Cyclotron.
In terms of end user, the industry is segregated into Hospital, Specialized Clinics and Pharmaceutical Companies
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East and Africa (MEA) have been covered in the report.
The global sales of medical cyclotrons is projected to witness CAGR of 6.4% between 2025 and 2035.
The global medical cyclotron sales stood at USD 232.4 million in 2024.
The global sales of medical cyclotron is anticipated to reach USD 636.7 million by 2035 end.
China is expected to show a CAGR of 4.2% in the assessment period.
The key players operating in this sector include Sumitomo Heavy Industries, Ltd., General Electric Company, IBA RadioPharma Solutions, Advanced Cyclotron Systems Inc., Best Medical International Inc., Siemens AG, Varian Medical Systems Inc., Ionetix Corporation, Alcen, and Isosolution Inc.
| Estimated Market Size (2025E) | USD 0.63 billion |
|---|---|
| Projected Market Value (2035F) | USD 4.26 billion |
| Value-based CAGR (2025 to 2035) | 23.1% |
| Market Value for 2023 | USD 7,725.0 million |
|---|---|
| Market Value for 2033 | USD 14,960.9 million |
| Market CAGR (2023 to 2033) | 6.8% |
| Market Size, 2023 | USD 48,626.2 million |
|---|---|
| Market Size, 2033 | USD 103,052.3 million |
| Value-based CAGR (2023 to 2033) | 7.8% |
| Market Size (2022) | USD 572.54 Million |
|---|---|
| Market Projected Size (2032) | USD 1158.26 Million |
| Market Value CAGR (2022 to 2032) | 7.3% |
Explore Pharmaceuticals Insights
View Reports
Medical Cyclotron Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
